An update from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.
Neuren Pharmaceuticals Limited has announced an update regarding its ongoing on-market buy-back program. As of the latest notification, the company has repurchased a total of 1,022,826 ordinary fully paid securities, with an additional 89,887 securities bought back on the previous day. This buy-back initiative is part of Neuren’s strategy to optimize its capital structure and potentially enhance shareholder value.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental and neurodegenerative disorders. The company is listed on the Australian Securities Exchange under the code NEU.
YTD Price Performance: 9.15%
Average Trading Volume: 647
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $1B
For detailed information about NEU stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com